Synthesizing a drug-organic-acid-anhydride conjugate using docetaxel as a drug, including: mixing aconitic anhydride with a chlorinating reagent to produce a first mixture; dissolving the first mixture in an organic solvent to produce a dissolved mixture; stirring the dissolved mixture; evaporating the organic solvent from the dissolved mixture to produce a second mixture; washing the second mixture with an impurity remover to remove impurities and to produce an aconitic anhydride chloride solution; and mixing the docetaxel with the aconitic anhydride chloride solution to produce the drug-organic-acid-anhydride conjugate.

Disclosed herein, inter alia, are trioxolane compounds and methods of using the same for treatment and detection of diseases.

Disclosed herein, inter alia, are trioxolane compounds and methods of using the same for treatment and detection of diseases.

Disclosed herein, inter alia, are prodrug compositions and methods of using the same for treatment and detection of disease. Specifically, disclosed herein is a compound of formula (I) having spiro-fused 1,2,4-trioxolane and piperidine rings, namely, 1,2,4-trioxa-8-azaspiro[4.5] decane. Also disclosed is a pharmaceutical composition containing the compound and a pharmaceutically acceptable carrier. ##STR00001##

Disclosed herein, inter alia, are prodrug compositions and methods of using the same for treatment and detection of disease. Specifically, disclosed herein is a compound of formula (I) having spiro-fused 1,2,4-trioxolane and piperidine rings, namely, 1,2,4-trioxa-8-azaspiro[4.5] decane. Also disclosed is a pharmaceutical composition containing the compound and a pharmaceutically acceptable carrier. ##STR00001##

A method for producing jet range hydrocarbons may include reacting at least a portion a fatty acid stream comprising C18:1 free fatty acid with ozone in an ozonolysis unit to form at least a C18:1 ozonide intermediate; introducing the C18:1 ozonide intermediate into a reactor, wherein at least a portion of the C18:1 ozonide intermediate is reacted with a reductive agent to produce oxidized products comprising azelaic acid and nonanoic acid; and introducing the oxidized products into a hydrotreating unit, wherein at least a portion of the oxidized products is hydrotreated to produce a paraffin product comprising nonane.

A method for producing jet range hydrocarbons may include reacting at least a portion a fatty acid stream comprising C18:1 free fatty acid with ozone in an ozonolysis unit to form at least a C18:1 ozonide intermediate; introducing the C18:1 ozonide intermediate into a reactor, wherein at least a portion of the C18:1 ozonide intermediate is reacted with a reductive agent to produce oxidized products comprising azelaic acid and nonanoic acid; and introducing the oxidized products into a hydrotreating unit, wherein at least a portion of the oxidized products is hydrotreated to produce a paraffin product comprising nonane.

Disclosed herein, inter alia, are prodrug compositions and methods of using the same for treatment and detection of disease. Specifically, disclosed herein is a compound of formula (I) having spiro-fused 1,2,4-trioxolane and piperidine rings, namely, 1,2,4-trioxa-8-azaspiro[4.5] decane. Also disclosed is a pharmaceutical composition containing the compound and a phannaceutically acceptable carrier.

##STR00001##

Disclosed herein, inter alia, are prodrug compositions and methods of using the same for treatment and detection of disease. Specifically, disclosed herein is a compound of formula (I) having spiro-fused 1,2,4-trioxolane and piperidine rings, namely, 1,2,4-trioxa-8-azaspiro[4.5] decane. Also disclosed is a pharmaceutical composition containing the compound and a phannaceutically acceptable carrier.

##STR00001##

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compound that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to the prevention and treatment of Alzheimer's disease